Form 4 for ORMP ORAMED PHARMACEUTICALS INC.

Accepted 2021-08-06 00:00:00 ET · period of report 2021-08-04 · accession 0001213900-21-040761 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2021-08-06	2021-08-04	ORMP	Rabinowitz Michael	Chief Commercial Off	A - Grant	$0.00	+100.0K	100.0K	New	$0
D	2021-08-06	2021-08-04	ORMP	Rabinowitz Michael	Chief Commercial Off	A - Grant	$0.00	+100.0K	100.0K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-08-04	A	A	100,000	$0.00	100,000	D	—	—	(F1) Represents common stock underlying Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. (F2) The RSUs will vest as follows: 33,333 shall vest if the closing price per share of the Issuer's common stock will be $15 for at least 20 days, 33,333 shall vest if the closing price per share of the Issuer's common stock will be $25 for at least 20 days, and 33,334 shall vest if the Issuer consummates an arm's length licensing or other strategic transaction, that includes its phase 3 oral insulin product, for no less than $50,000,000 in upfront cash (including proceeds from any upfront stock equity purchase).
2	Derivative	Stock Option (right to buy)	2021-08-04	A	A	100,000	$0.00	100,000	D	$15.10 · — to 2031-08-04	100,000 Common Stock	(F3) The Stock Options will vest in five installments as follows: 12,500 shall vest on December 31, 2021, 25,000 shall vest on each of December 31, 2022, December 31, 2023 and December 31, 2024, and 12,500 shall vest on August 4, 2025.